OUR MISSION

OLTRE BIOMEDICAL Inc. was established with the expressed purpose of funding and pursuing clinical trials in Canada and the USA for its promising drug treatment for respiratory diseases. The more immediate interest and focus will be on the urgently needed treatment of COVID-19 patients in distress.

​

Cavaltinib™, the subject drug, displays novel pharmacology and has been shown in recent medical discoveries by Biologic Pharmamedical Research, a collaborating biotech corporation, to be a fit as a drug candidate for COVID-19 patient treatment. This candidate drug has been run through a research program that was designed to study key drug targets involved in the regulation of the immune system and inflammatory activity.

​

Research has already shown Cavaltinib™ irrefutably inhibits, the NF-kappa-B Signalling Pathway through mechanisms discovered by, Biologic Pharmamedical’s principle scientist, Franco Cavaleri. A discovery by a Canadian scientist in a Canadian drug research program. As a consequence of its down-regulation the inhibition of several downstream cytokines ensues; cytokines central to the ‘cytokine storm’ phenomenon characteristic of the COVID-19 pathology (IL-1, IL-2, IL-3, IL-6, and several other cytokines).

​

OLTRE's mission is to demonstrate this activity in the context of COVID-19 patients in a clinical setting and further assert that this pharmacology can play a significant role in these patients to circumvent morbidity and mortality. The objective is to expand the indications to other respiratory diseases using this mechanism and path to drug status.

​

​

BEYOND CAVALTINIB™ & COVID

​

Upon reaching drug status for the treatment of respiratory diseases like COVID with the patented Cavaltinib™, we will work to add new and additive indications with this drug; addendum treatments we are confident, based on experience, can be effective for ulcerative colitis, Crohn's disease, rheumatoid arthritis and more.  Furthermore, Biologic Pharmamedical Research, the parent company of OLTRE, has acquired patents and approval for over-the-counter use for as many as FIVE novel technologies over the last few decades.  Additionally, Biologic continues to develop and curate new patents in this class of treatment.  OLTRE Biomedical will serve as the organization to take variants of these already proven and approved patented treatments to drug status in much the same way as we are working Cavaltinib™ to the finish line.  We have lots of additional opportunities to work with and work for in the immediate future.  These additional alternatives can be taken in multiples at the same time if resources are available. 

​